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Abstract 
Although GH- and PRL-secreting pituitary adenomas are considered benign, in many 
patients, tumor growth and/or invasion constitute a particular challenge. In other tumors, 
progression relies in part on dysfunction of intercellular adhesion mediated by the large 
family of cadherins. In this study, we have explored the contribution of cadherins in GH and 
PRL adenoma pathogenesis, and evaluated whether this class of adherence molecules was 
related to tumor invasiveness. We have first established, by qPCR and 
immunohistochemistry, the expression profile of classical cadherins in normal human 
pituitary gland. We show that the cadherin repertoire is restricted and cell-type specific. 
Somatotrophs and lactotrophs express mainly E-cadherin and cadherin 18, while N-cadherin 
is present in the other endocrine cell types. This repertoire undergoes major differential 
modification in GH and PRL tumors: E-cadherin is significantly reduced in invasive GH 
adenomas, and this loss is associated with a cytoplasmic relocalization of cadherin 18 and 
catenins. In invasive prolactinomas, E-cadherin distribution is altered and is accompanied by  
a mislocalization of cadherin 18, beta-catenin and p120 catenin. Strikingly, de novo 
expression of N-cadherin is present in a subset of adenomas and cells exhibit a mesenchymal 
phenotype exclusively in invasive tumors. Binary tree analysis, performed by combining the 
cadherin repertoire with the expression of a subset of known molecular markers, shows that 
cadherin/catenin complexes play a significant role in discrimination of tumor invasion.  
Introduction 
Pituitary tumors represent up to 10-15% of intracranial neoplasms with a prevalence of 0.1% 
in the overall population (1). These common tumors display various clinical behaviors and 
most are sporadic, however familial isolated pituitary adenomas have been described (1, 2). 
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Although usually benign, they cause significant morbidity due to mass effects, local 
expansion and/or hormonal deficiency or excess. Among the various pituitary tumor 
subtypes, prolactinomas are the most common, accounting for up to 45% of pituitary 
adenomas presenting at clinic (3). Prolactinomas are easily controlled in the majority of cases 
by pharmacological treatment with dopamine agonists. However, invasive prolactinomas can 
be resistant to dopamine agonist treatment and have lower cure and higher recurrence rates 
compared with non-invasive prolactinomas (4). GH-secreting adenomas represent 10-15% of 
pituitary adenomas (5) and cause acromegaly and gigantism. Various treatment options are 
available for acromegaly, including for medical therapy, somatostatin analogs, dopamine 
agonists, and GH receptor antagonists. Several mechanisms and predictors for somatostatin 
resistance have been reported to date (6) and involve, for example, alterations in somatostatin 
receptor subtype expression patterns (7) and a decrease in E-cadherin expression (8). Most 
pituitary tumors in acromegalic patients are benign, nevertheless, many tumors can behave 
more aggressively and require multiple treatments (9). 
The prediction of invasive behavior in pituitary adenomas is complex and challenging, 
and many studies are dedicated to the identification of potential biomarkers (10-13). In a 
recent retrospective multicentre case–control study, invasion has been shown to be a major 
prognostic factor in predicting recurrence/progression following treatment of pituitary tumors 
by surgery (14). To date, no single marker has been identified to independently predict tumor 
behavior, although some markers appear to be specific for different adenoma subtypes. 
Indeed, large scale studies have shown that a combination of markers is more useful to 
predict tumor behavior, especially aggressiveness (15). However, the identification of other 
biomarkers is still necessary and would help optimization of therapeutic strategies. The tumor 
microenvironment, in particular intercellular adhesion, plays a key role during tumor 
progression and invasion, and cadherin/catenin complex dysfunction is a major contributor to 
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cancer progression. Abnormal or reduced expression of these complexes is observed in 
various cancers (16). For instance, the loss of E-cadherin is a hallmark of many epithelial 
cancers and has been associated with invasiveness, metastasis, and poor prognosis (16, 17). 
Loss of E-cadherin is often associated with de novo expression of mesenchymal cadherins. 
This process has multiple consequences for the phenotype and behavior of cells, and 
constitutes one major aspect of the cancer-related Epithelial Mesenchymal Transition (EMT) 
process (18). Epithelial E-cadherin expression has been investigated in several pituitary 
adenoma subtypes and its alteration could contribute to invasiveness of pituitary adenomas 
(8, 19, 20). In addition, molecular studies have suggested that EMT may play an important 
role in GH adenoma progression (21-24). 
The large superfamily of cadherin proteins includes classical cadherins, protocadherins 
and cadherin-related molecules. Their specific roles in initiation and progression of many 
tumors is starting to be elucidated, and has revealed that they can influence tumor behavior 
by multiple complex mechanisms (16, 25). However, their expression and function in the 
normal as well as impaired human pituitary gland still needs to be established. We have 
previously demonstrated that the murine pituitary gland is a highly organized structure (26), 
and that cadherins are involved in this specialized organization (27). We have shown that a 
restricted cadherin repertoire is present in the anterior pituitary, and that each cell type 
expresses a specific subset of cadherins. This repertoire is plastic during pituitary tissue 
remodeling, especially during development and sexual maturation. These findings and the 
recent report that abnormal hormone secretion in hyperfunctioning adenomas could be due to 
spatial and functional disorganization of the pituitary gland (28) led us to hypothesize that 
alterations in the repertoire of cadherins may contribute to pathology. Here, we first 
established the pattern of cadherin expression in normal human pituitary gland by screening 
more than 20 members of the cadherin family. We then examined whether this repertoire was 
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modulated in tumors, focusing on 2 major subtypes of pituitary adenomas, GH-secreting 
adenomas and prolactinomas. A decrease or loss of E-cadherin expression was correlated 
with invasiveness in GH tumors and was related to a cytoplasmic redistribution of 
cadherin/catenin complexes. We show that de novo expression of N-cadherin takes place in a 
subset of adenomas, and cells adopt a mesenchymal phenotype unique to invasive tumors. 
Correlation of cadherin expression with known biomarkers of invasion and binary tree 
analysis indicates that the cadherin repertoire can differentiate tumor invasive behavior.  
Materials and methods 
Patients and samples  
cDNA from normal pituitary glands (n = 3) was obtained from La Timone Hospital 
(Marseille, France) and tissue sections from normal pituitary glands  (n = 3) were obtained 
from Legal Medecine Department at Lapeyronie Hospital (Montpellier, France) and 
Pathological Anatomy and Cytology Departement at Gui De Chauliac Hospital (Montpellier). 
GH- and PRL-secreting adenoma fragments were obtained from 52 patients who had 
undergone transsphenoidal surgery at two University hospitals (La Timone Hospital - 
Marseille, and Pellegrin-Tripode Hospital - Bordeaux, France). Samples from 20 male and 32 
female patients (mean age: 39 ± 16 years, range 3 - 68 years) were collected from Pathology 
Departments by the Tumor Banks of both hospitals after patient information by the physician 
and registration of consent according to the guidelines of the French Bioethical law for non-
interventional research studies. Then, samples were anonymised, distributed for the present 
research and processed for RNA extraction or tissue sections. The diagnoses of clinical 
acromegaly or hyperprolactinemia were made according to clinical and hormonal evaluation 
with additional information provided by histological assessment and immunohistochemical 
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staining for all anterior pituitary hormones on tumoral fragments. Tumors were evaluated on 
the basis of preoperative magnetic resonance imaging scans and defined as invasive on the 
basis of the cavernous sinus invasion. Based on this parameter, 14 patients had invasive GH-
secreting adenoma and 13 patients had non-invasive GH-secreting adenoma, 8 patients had 
invasive prolactinoma and 17 patients had non-invasive prolactinoma. Patient clinical 
characteristics are shown in Table S1. 
Real-time RT-PCR 
Total RNA was extracted and then reverse-transcribed as previously described (29). Specific 
primers for qRT-PCR were designed using the Primer Express 3.0 software, the sequences 
are shown in Table S2. Cadherin/catenin expression was analysed on all samples (n=52), and 
the expression for the other genes was performed on 50/52 samples since the quantity of 
cDNA was too low for two invasive GH tumors. For gene expression quantification, primers 
for each gene of interest (5 μl, 300 or 900 nM final) were first evaporated in 384-well plates 
using a Vacufuge® vacuum concentrator (Eppendorf), then resuspended in 2.5 μl 
LightCycler*480 SYBR Green 1 Master mix 2X (Roche) and 5 ng of sample RNA in a total 
reaction volume of 5 μl. PCR reactions were performed by using the LightCycler 480 system 
with the following conditions: an initial denaturation step for 10 min at 95°C, followed by 45 
cycles of 95°C for 15 s and 60°C for 30 sec. Specificity for each PCR reaction was assessed 
by melting curve analysis of amplicons. For each sample, values were determined from 
triplicate measurements. Data were analyzed using the threshold cycle (Ct) relative 
quantification method (LightCycler 480 SW 1.5 software). Expression of gene of interest was 
normalized to the expression levels of three housekeeping genes RPLP0, RPL31, and 
GAPDH, according to the formula: 2-[Ct(gene)-arithmetic mean (Ct(RPLP0), Ct(RPL31), 
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Ct(GAPDH))]x10000. Estimation of the stability of references genes was established using 
the geNorm method (30).  
Antibodies, Immunohistochemistry and Confocal microscopy 
The primary antibodies and their dilutions used in this study were as follows: mouse 
monoclonal against E-cadherin (1:150; clone 36B5, ThermoScientific); mouse monoclonal 
against N-cadherin (1:250; clone 3B9, Zymed Laboratories Inc); rabbit polyclonal against 
CDH18 (1:25; HPA014365, Sigma), mouse monoclonal against beta-catenin (1:200; clone14, 
Transduction Laboratories), rabbit polyclonal against beta-catenin (1:50, H102, Santa Cruz 
Biotechnology), mouse monoclonal against p120 catenin (1:500; pp120 clone98, 
Transduction Laboratories). Guinea pig polyclonal antibodies against each pituitary hormone 
(1:5000) were obtained from the National Hormone and Peptide Program, NIDDK and Dr 
AF Parlow, (Torrance, CA, USA). For cadherins or catenins immunostaining, tyramide signal 
amplification (TSA Plus Cyanine 3; PerkinElmer) was applied according to the 
manufacturer’s directions. After deparaffinizing and rehydrating, heat-induced epitope 
retrieval was performed in sodium citrate buffer (0.01 M, pH 6.0). Slides were incubated in 
1% hydrogen peroxide to quench endogenous peroxidases and washed in phosphate-buffered 
saline (PBS). Sections were incubated overnight at 4°C with primary antibodies in PBS 
containing 0.1% Triton X-100 and 2% bovine serum albumin and 2% normal donkey serum 
(Sigma). After rinsing in PBS, slides were incubated for 2h with appropriate peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). After washing, 
tissue sections were incubated for 15 min with cyanine 3-conjugated tyramide in the diluent 
supplied in the kit, carefully washed and mounted in Mowiol (Calbiochem). For double 
immunofluorescence, cadherin immunostaining was done as above, and hormone 
immunostaining was then performed with specific guinea pig antibodies detected with Alexa 
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488-conjugated donkey anti-guinea pig IgG (Molecular Probes). Sections were observed 
under a LSM510 Zeiss Confocal laser scanning microscope equipped with a krypton/argon 
mixed gas laser. The organization of the immunostained structures was studied on 
reconstructed images made by projecting 1-µm z-stacks of 2-3 consecutive confocal images. 
Unaltered digitalized images were transferred to a computer and Adobe Photoshop software 
was used to prepare final figures. 
Binary Tree Analysis 
Tumor analysis through binary trees (31) was performed using the rpart package in R 
(http://CRAN.R-project.org/package=rpart) (32). Invasiveness was used as output and 8 
genes from 50 samples were used as predictors. Pruning of the tree was performed after 
leave-one-out cross-validation to prevent overfitting the tree to the training data. More 
information is available in the Appendix S1.   
Statistical methods  
Normal distribution of the variables was assessed by Shapiro-Wilk test. The comparisons 
between gene expression were done with Mann-Whitney U test. Reported correlations were 
performed using Spearman’s correlation coefficient. 
Results 
Cadherin repertoire in human pituitary  
Most studies on human pituitary adenomas have focused on E-cadherin expression and its 
role in tumorigenesis and tumor behavior. To investigate whether other members of the 
cadherin family could be involved in pituitary adenoma pathogenesis, we first examined the 
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pattern of cadherin expression in normal human pituitary. We focused our study on type I and 
type II cadherins, characterized by a short ectodomain containing five extracellular cadherin 
repeats and two highly conserved intracellular domains required for beta-catenin and p120 
catenin binding. Cadherin 13, a GPI-linked truncated isoform, and cadherin 16 and 17 
containing 7 extracellular cadherin repeats (25) were also studied. We first quantified 
cadherin mRNA levels by real-time PCR. Figure 1A shows that among the 21 cadherins 
tested, cadherin 5 (CDH5, specific from endothelial cells), N-cadherin (CDH2), cadherin 18 
(CDH18), and E-cadherin (CDH1) exhibit moderate to high levels of mRNA. Relative 
expression for CDH5, N-cadherin, CDH18 and E-cadherin was 105 ± 35, 233 ± 66, 362 ± 79 
and 696 ± 47, respectively. The other cadherins were either absent or expressed at very low 
levels. Since cadherins are associated with the regulatory intracellular components beta-
catenin and p120 catenin, we also quantified their relative mRNA expression levels. Relative 
expression was 534 ± 73 for beta-catenin and 52 ± 10 for p120 catenin (data not shown). To 
establish the distribution of cadherin/catenin complexes within the pituitary gland, we 
performed immunohistochemistry on sections from normal pituitary double-stained for the 
different hormones secreted by the gland and either beta-catenin, p120 catenin, or the 3 major 
cadherins present in the gland, E-cadherin, N-cadherin and cadherin 18. Beta-catenin and 
p120 catenin were readily detected and broadly expressed throughout the gland. The staining 
was mainly present at the cell membrane and co-staining with the hormones showed that all 
endocrine cell types express these two catenins (data not shown). In contrast, cadherins 
displayed cell-type specific pattern of distribution (Fig 1B-P). Staining for E-cadherin and 
cadherin 18 was detected mainly at the plasma membrane from somatotrophs (Fig 1B and F) 
and lactotrophs (Fig 1C and G) and was either absent or present at low levels in corticotrophs 
(Fig 1H and N), thyrotrophs (Fig 1I and O) or gonadotrophs (Fig 1J and P). Conversely, N-
cadherin staining was localized at the membrane in corticotrophs (Fig 1K), thyrotrophs (Fig 
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1L) and gonadotrophs (Fig 1M) and barely detectable in somatotrophs (Fig 1D) and 
lactotrophs (Fig 1E). Thus, somatotrophs and lactotrophs express mainly E-cadherin and 
cadherin 18, whilst N-cadherin is most prominent in the other endocrine cell types. 
 
Differential alteration of cadherin/catenin complexes in GH and PRL-
secreting pituitary adenomas 
We analyzed the cadherin expression profile in pituitary GH and PRL-secreting 
adenomas using q-PCR. We tested the 21 members and could not detect de novo expression 
of cadherins in tumors, only E-cadherin, N-cadherin and cadherin 18 mRNAs were present. 
It appeared that E-cadherin mRNA levels were significantly reduced in invasive GH 
adenomas as compared to non-invasive tumors (Fig 2A). In 10 of 14 (71%) invasive GH 
adenomas, E-cadherin mRNA was barely detectable. Cadherin18 mRNA levels were similar 
in non-invasive and invasive GH tumors (Fig 2B) and were not strikingly different from 
those quantified in normal pituitaries (Fig 1A). No significant differences were observed for 
beta-catenin and p120 catenin mRNA levels in non-invasive and invasive GH tumors (data 
not shown). We then examined the distribution of cadherin/catenin complexes in GH 
adenomas. In GH non-invasive tumors, the staining for E-cadherin, cadherin 18, beta-catenin 
and p120 catenin was mainly detected at the plasma membrane of the cells (Fig 2C-F). In 
contrast, the pattern of distribution of cadherin/catenin complexes was very different in GH 
invasive tumors, and was characterized by an absence of E-cadherin staining and low to 
strong cytoplasmic staining for cadherin 18, beta-catenin and p120 catenin (Fig 2G-J). Thus, 
the loss of E-cadherin is associated with a cytoplasmic redistribution of catenins, as 
previously reported in various tumor types (33), with a concomitant relocalization of cadherin 
18 from the membrane to the cytoplasm.  
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In contrast to GH adenomas, E-cadherin mRNA levels were not significantly different 
in non-invasive and invasive prolactinomas (Fig 3A). Cadherin18 mRNA levels (Fig 3B), as 
well as beta-catenin and p120 catenin mRNA levels (data not shown), were comparable in 
non-invasive and invasive prolactinomas. In non-invasive prolactinomas, E-cadherin, 
cadherin 18, beta-catenin and p120 catenin immunostainings were mainly present at the 
plasma membrane of the cells (Fig 3C-F). The staining for cadherin/catenin complexes was 
different and heterogeneous in invasive prolactinomas (Fig 3G-N). Cadherin/catenin 
complexes were expressed at the plasma membrane in some part of the tissue section (Fig 
3G-J). In some areas, E-cadherin membraneous staining was strongly reduced and the 
labeling was present in the cytoplasm (Fig 3K). The redistribution of E-cadherin was 
accompanied by a drastic alteration in the membraneous staining for cadherin 18, beta-
catenin and p120 catenin (Fig 3L-N), and some cytoplasmic labeling was present for cadherin 
18 and beta-catenin. Altogether, these results show that cadherin/catenin complexes were 
differentially regulated in GH and PRL adenomas. 
Interestingly, N-cadherin, which is not detectable in GH and PRL cells in normal 
tissue, was expressed in a subset of GH and PRL adenomas. N-cadherin mRNA was present 
in 55% (15 of 27) of GH tumors (i.e. relative mRNA expression > 10; Fig 4A). Similarly, 
72% (18 of 25) of prolactinomas expressed N-cadherin mRNA (Fig 4B). We performed 
immunohistochemistry to visualize N-cadherin distribution in these tumors expressing N-
cadherin mRNA. N-cadherin staining was restricted to the cell membrane in non-invasive 
tumors (Fig 4C and E). In invasive tumors, although some cells exhibited a cytoplasmic N-
cadherin staining, labeling was present predominantly at the plasma membrane (Fig 4D and 
F). In addition, it is worth noting that N-cadherin positive cells exhibited morphological 
changes in invasive tumors, reminiscent of the profound structural modifications affecting 
cells which undergo EMT (34). Indeed, in invasive tumors, N-cadherin positive cells 
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displayed an irregular, elongated mesenchymal shape, while they showed an epithelial 
phenotype in non-invasive tumors. 
 
Discrimination of GH and PRL-secreting adenomas based on invasive 
behavior by combining cadherin repertoire with markers of invasion 
In an attempt to discriminate tumors on the basis of invasiveness, and to evaluate the 
importance of the expression profiles of cadherin/catenin complexes in determining tumor 
phenotype, we combined the patterns of expression of these adhesion molecules with those of 
a subset of well-established pituitary adenoma markers. We first examined the expression 
profiles of ESRP1, LGALS3 and PTTG1. ESRP1 (Epithelial Splicing Regulatory Protein 1) 
has been recently proposed to act as a key regulator of the EMT process in GH adenomas 
(22). Galectin 3 (LGALS3) is expressed in PRL and ACTH adenomas (35), and two recent 
studies have proposed that it is a strong predictive factor of recurrence/progression of PRL 
adenomas (36, 37). PTTG1 (Pituitary Tumor Transforming Gene 1) plays an important role 
in pituitary tumorigenesis, is overexpressed in pituitary adenomas and has been proposed to 
be a biomarker of aggressive pituitary adenomas (15, 38).  
Fig 5A shows that in GH-secreting adenomas, ESRP1 expression was significantly 
reduced in invasive tumors compared to non-invasive adenomas. ESRP1 was also present in 
prolactinomas and its expression was related to tumor invasiveness (Fig 5D). In a recent 
study of GH adenomas, it was reported that ESRP1 and E-cadherin mRNAs were correlated 
and that silencing of Esrp1 in GH3 cells induced a significant decrease in E-cadherin 
expression (22). We found that in GH-secreting adenomas E-cadherin expression was 
positively associated with ESRP1 expression (R = 0.87, P < 0.0001), while no correlation was 
observed in prolactinomas (R = 0.33, P = 0.112). In addition, we observed no significant 
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association between LGALS3 and PTTG1 expression and tumor invasiveness in both types of 
adenomas (Fig 5B, C, E and F). 
We then analyzed the gene expression profiles to establish binary trees of adenomas 
based on the invasiveness behavior of the tumors. The binary tree for tumor invasion is 
shown on Fig 6A and indicates that different patterns of gene expression allow distinct 
separation of invasive and non-invasive tumors with an acceptable misclassification rate 
(12%). The results indicate that the cadherin repertoire plays a significant role in 
distinguishing GH and PRL tumors in regards to their invasive behavior. The importance of 
each gene for the construction of the binary tree is illustrated in Fig 6B and shows that 
ESRP1 and E-cadherin are the major genes distinguishing the invasiveness behavior of the 
tumors.  
  
Discussion 
We report here that human normal pituitary gland exhibits a limited and cell-type specific 
cadherin expression profile. In tumors, this cadherin repertoire undergoes major remodeling 
and is differentially altered in GH-secreting adenomas and prolactinomas. E-cadherin 
expression is significantly reduced in invasive GH tumors and is correlated with a 
cytoplasmic redistribution of cadherin/catenin complexes. In invasive prolactinomas, E-
cadherin distribution is reshaped and is associated with a concomitant disorganization of 
cadherin/catenin complexes. In addition, a subset of adenomas has altered expression of N-
cadherin, and morphological changes evocative of EMT-like process are peculiar to invasive 
tumors. Using binary tree analysis, we demonstrate that this class of adhesion molecules, in 
association with known pituitary adenoma markers, allows discrimination of tumors by their 
invasive behavior.  
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The investigation of the cellular expression and distribution of more than 20 members 
of the superfamily of cadherin proteins has shown that the cadherin repertoire of normal 
human pituitary is restricted, since only E-cadherin, N-cadherin and cadherin 18 were 
detected. This is in agreement with previous studies of the expression of E- and N-cadherin in 
normal tissue (39-42), although in these, the cellular expression of E- and N-cadherin within 
the normal gland was either not investigated or incomplete for the different endocrine cell 
types. Here we have included evaluation of the cellular distribution of these adhesion 
molecules and showed that the cadherin expression pattern is cell-type specific. 
Somatotrophs and lactotrophs express mainly E-cadherin and cadherin 18, while N-cadherin 
is present in the other endocrine cell types. Therefore, even if the cadherin repertoire is quite 
different in humans and rodents it appears that the different cellular types of the human 
pituitary gland can be characterized by a defined combinatorial expression of different 
subsets of cadherins as previously reported in the murine pituitary (27). 
This repertoire of adhesion molecules is highly altered in tumors and, interestingly, 
GH-secreting adenomas and prolactinomas display differential modulation of 
cadherin/catenin complex expression. Such patterns of expression specific of tumor type have 
been reported for somatostatin receptor subtypes (7). These results suggest that, although GH 
and PRL cells derive from the same lineage (43), tumorigenesis process involves a 
multiplicity of underlying mechanisms probably specific for the tumor subtype. It is worth 
noting that these two types of tumors do not present de novo expression of the cadherins not 
detected in the normal gland. We show that E-cadherin mRNA levels were not significantly 
different in invasive and non-invasive prolactinomas. In contrast, E-cadherin mRNA levels 
were significantly reduced in invasive compared with non-invasive GH-secreting tumors. 
Alteration of E-cadherin expression has been shown in pituitary adenomas (8, 19, 40), and is 
now well characterized in GH-producing adenomas (8, 42, 44, 45) and is not correlated to 
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pre-operative medical treatment (8). In our study, we have observed that ESRP1 expression 
was significantly reduced in GH invasive tumors and E-cadherin expression was positively 
associated with that of ESRP1. This is in good agreement with a previous study reporting that 
ESRP1, an important regulator of EMT, correlates with E-cadherin mRNA in a large cohort 
of patients with acromegaly (22). We have extended this analysis since we have shown that 
ESRP1 is also expressed in prolactinomas with similar levels than in GH-secreting tumors, 
however no correlation between ESRP1 and E-cadherin was observed in prolactinomas, 
suggesting that distinct regulatory mechanisms for E-cadherin expression might take place in 
both types of tumors.  
In approximately 70% of PRL and 55% of GH adenomas we observed expression of N-
cadherin, a cadherin expressed in the normal gland by endocrine cell types other than GH 
and PRL cells. Interestingly, N-cadherin expression was previously reported by Rubinek et 
al. (46) in 8 of 12 GH adenomas and 1 of 7 prolactinomas. The inappropriate up-regulation of 
N-cadherin in some cancer cells has been shown to promote motility and invasion (47, 48), 
and induces major effects on cell phenotype and behavior (16, 18). A high level of N-
cadherin expression is often associated with poor prognosis (16). In our study, N-cadherin 
positive cells adopt morphological features consistent with a mesenchymal phenotype in 
invasive tumors, suggesting that an EMT-like process might occur in some pituitary 
adenomas and might be associated with GH and PRL progression. Epithelial cells that 
undergo EMT are transcriptionally reprogrammed, which in turn leads to decreased adhesion, 
enhanced migration or invasion and increased resistance to apoptosis (49). Previous cellular 
and molecular studies suggest that potential EMT might take place in pituitary tumors (21, 
22, 50), the morphological changes that we report here in invasive tumors strengthen these 
results.  
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The differential alterations of cadherin/catenin complex expression in invasive and non-
invasive adenomas led us to analyze this class of adhesion molecule as a relevant parameter 
for the discrimination of pituitary tumors based on the invasive behavior. To address this 
point, we have chosen a gene candidate approach by analyzing cadherin expression in 
association with the pattern of expression of known molecular markers related to pituitary 
tumor behavior and susceptibility to organize tumors. Of note, the number of genes used in 
binary tree analysis is not limited and emerging studies of exome array analysis in pituitary 
adenomas (51, 52) would enable to increment the number of genes in future studies. Such 
strategies could be applied to invasive behavior, resistance to dopamine agonists or 
somatostatin receptor analogues, tumor recurrence... The binary tree based on the invasive 
behavior of the tumors shows that the two types of tumors can be distinguished regarding 
their pattern of gene expression with a low misclassification rate. ESRP1 and E-cadherin play 
an important role in the establishment of the binary tree. Thus, these results show that 
combining the pattern of cadherin expression with known biomarkers can discriminate the 
invasive behavior of pituitary adenomas. Cadherin/catenin complexes are significant factors 
to separate invasive from non-invasive GH and PRL tumors.  
We report here that cadherin repertoire contributes to the discrimination of GH and 
PRL adenomas in regards to tumor invasiveness. Since we have shown that cadherin profiles 
are cell-type specific, it would be of interest to examine whether this class of adhesion 
molecules could be useful to analyze other pituitary adenoma subtypes. In addition, as 
prediction of pituitary tumor recurrence or invasiveness is problematic, future studies 
determining if tumors exhibiting de novo expression of N-cadherin have a tendency to recur 
could bring new insights in the research of prognosis biomarkers. Finally, it would be 
interesting to elucidate the role of N-cadherin in pituitary adenoma pathogenesis, especially 
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in tumors with induced expression of N-cadherin, since it is possible that the invasion process 
in this type of tumors relies on N-cadherin up-regulation.  
In conclusion, we show here that the cadherin expression profile in normal human 
pituitary gland is restricted and cell-type specific, and displays major differential alterations 
in GH and PRL tumors. A subset of GH and PRL tumors express N-cadherin, and 
morphological changes are suggestive of EMT-like process and are unique to invasive 
tumors. The association with known molecular markers shows that this cadherin repertoire 
plays a substantial role in the discrimination of GH and PRL tumors based on tumor invasive 
behavior. 
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Figure legends 
Fig 1. Cadherin expression profile and cellular distribution in normal human pituitary gland. 
(A) Cadherin mRNA levels were quantified by real time PCR and results are presented as 
mean ± SEM. E-cadherin (CDH1), N-cadherin (CDH2) and cadherin 18 (CDH18) exhibited 
the highest levels of expression. (B-P) CDH1, CDH2 and CDH18 (red) distribution in 
hormone-producing cells (green) of normal human pituitary gland. (B, D and F) Confocal 
images showing double immunofluorescence labeling of pituitary sections with specific 
antibodies against GH and CDH1 (B), CDH2 (D) or CDH18 (F). (C, E and G)  Confocal 
images showing double immunofluorescence labeling of pituitary sections with specific 
antibodies against PRL and CDH1 (C), CDH2 (E) or CDH18 (G). To improve cadherin 
staining visibility, the red channel is shown alone on the left. (H-P) Confocal images showing 
double immunofluorescence labeling of pituitary sections with specific antibodies against 
ACTH (H, K and N), TSH (I, L and O) or LH-FSH (J, M and P) and CDH1 (H-J), CDH2 (K-
M) or CDH18 (N-P). CDH1 and CDH18 were mainly detected in somatotrophs and 
lactotrophs, whilst CDH2 was prominent in corticotrophs, thyrotrophs and gonadotrophs. 
Scale bar, 20 μm. 
Fig 2. E-cadherin and cadherin 18 mRNA expression and cadherin/catenin complex 
distribution in GH-secreting adenomas. (A and B) Cadherin mRNA levels were quantified by 
real time PCR in non-invasive (NI, n = 13) and invasive (I, n = 14) GH-secreting adenomas. 
Results are presented as box plots with median value (line), the interquartile range (box) and 
the range of the data. *** P < 0.001. (C-J) Confocal images showing immunofluorescence 
labeling of non-invasive (C-F) and invasive GH-secreting adenomas (G-J) with specific 
antibodies against E-cadherin (C and G), cadherin 18 (D and H), beta-catenin (E and I) and 
p120 catenin (F and J). Scale bar, 20 μm. 
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Fig 3. E-cadherin and cadherin 18 mRNA expression and cadherin/catenin complex 
distribution in PRL-secreting adenomas. (A and B) Cadherin mRNA levels were quantified 
by real time PCR in non-invasive (NI, n = 17) and invasive (I, n = 8) prolactinomas. Results 
are presented as box plots with median value (line), the interquartile range (box) and the 
range of the data. (C-N) Confocal images showing immunofluorescence labeling of non-
invasive (C-F) and invasive prolactinomas (G-N) with specific antibodies against E-cadherin 
(C, G and K), cadherin 18 (D, H and L), beta-catenin (E, I and M) and p120 catenin (F, J and 
N). Scale bar, 20 μm. 
Fig 4. N-cadherin mRNA expression and distribution in GH-secreting adenomas and 
prolactinomas. (A and B) N-cadherin mRNA levels were quantified by real time PCR in non-
invasive (NI, n = 13) and invasive (I, n = 14) GH-secreting adenomas (A), and in non-
invasive (NI, n = 17) and invasive (I, n = 8) prolactinomas (B). Results are presented as box 
plots with median value (line), the interquartile range (box) and the range of the data. (C-F) 
Confocal images showing immunofluorescence labeling of non-invasive and invasive GH-
secreting adenomas and prolactinomas with N-cadherin antibody. Note the epithelial 
morphology of N-cadherin positive cells in non-invasive tumors (C and E) and the elongated 
and irregular shape of tumoral cells in invasive tumors (D and F). Scale bar, 20 μm.  
Fig 5. ESRP1, LGALS3, and PTTG1 mRNA expression in GH-secreting adenomas and 
prolactinomas. (A-C) Genes of interest were quantified by real time PCR in non-invasive (NI, 
n = 13) and invasive (I, n = 12) GH-secreting adenomas. (D-F) Genes of interest were 
quantified by real time PCR in non-invasive (NI, n = 17) and invasive (I, n = 8) 
prolactinomas. Results are presented as box plots with median value (line), the interquartile 
range (box) and the range of the data. * P < 0.05, ** P < 0.01. 
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Fig 6. Binary trees of GH-secreting adenomas and prolactinomas based on the invasiveness 
behavior of the tumors. (A) Classification tree for tumor invasiveness. Numbers underneath 
the leaves show the number of invasive and non-invasive tumors in each group (I/NI). The 
misclassification rate of this tree is 12%. (B) Importance of each gene for the classification, 
as a measure of enhancement of branches associated with that gene. 
 
Supporting Information 
The following supplementary material is available: 
 
Table S1. Patient clinical characteristics. 
 
Table S2. Human primer sequences used for real-time PCR. 
 
Appendix S1. Protocol for binary tree analysis. 
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